Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and/or Refractory Multiple Myeloma: A Real-World Analysis

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-04-15 DOI:10.1016/j.clml.2025.04.008

Mihir N. Patel , Susan C. Locke , Caroline Falvey , Jesse D. Troy , Kris W. Herring , Amanda Bolgioni-Smith , Cherie Elcock , Laura Iadeluca , Cristiana Costa Chase , Cristina Gasparetto , Mark S. Newman , Thomas W. LeBlanc

{"title":"Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and/or Refractory Multiple Myeloma: A Real-World Analysis","authors":"Mihir N. Patel , Susan C. Locke , Caroline Falvey , Jesse D. Troy , Kris W. Herring , Amanda Bolgioni-Smith , Cherie Elcock , Laura Iadeluca , Cristiana Costa Chase , Cristina Gasparetto , Mark S. Newman , Thomas W. LeBlanc","doi":"10.1016/j.clml.2025.04.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Belantamab mafodotin is an anti-B cell maturation antigen (BCMA) immunoconjugate for patients with relapsed/refractory multiple myeloma (RRMM). Additional data on its treatment patterns, efficacy, and tolerability in real-world settings are needed.</div></div><div><h3>Patients and Methods</h3><div>This single-site, retrospective study examined 30 adults with multiple myeloma receiving care at Duke Cancer Institute who began belantamab mafodotin monotherapy between 8/5/2020 and 11/22/2022. We described baseline clinical characteristics, disease response (per International Myeloma Working Group [IMWG] criteria, as possible given available bone marrow biopsy data), belantamab mafodotin treatment patterns, and ocular adverse events (per the Keratopathy Visual Acuity [KVA] scale).</div></div><div><h3>Results</h3><div>Across 30 patients, the median number of lines of therapy was 4, 20 patients (87%) were triple-/quad-/penta-refractory, and 7 (23%) had high-risk cytogenetics (per IMWG criteria). Overall response rate was 67%. Progression occurred in 22 patients (73%); median progression-free survival was 9.5 months (95% CI 6.6-15.6). Median overall survival was not reached as of 3-year follow-up. Dose reduction occurred in 19 patients (63%); 65% were due to ocular adverse events, 30% hematologic adverse events. Cycle delay occurred in 28 (93%); 85% were due to ocular adverse events. Keratopathy (any grade) occurred in 28 (93%); 2% of events were grade ≥3. Visual acuity change (any grade) occurred in 27 (90%); 3.3% of events were grade ≥3. Treatment discontinuation from ocular toxicity occurred in 4 (13%).</div></div><div><h3>Conclusion</h3><div>Despite a high incidence of manageable keratopathy, these data demonstrate benefit in belantamab mafodotin in patients with RRMM over an extended time amid dose/cycle modifications.</div></div><div><h3>Registration: ClinicalTrials.gov</h3><div>NCT05986682.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 8","pages":"Pages e570-e579.e4"},"PeriodicalIF":2.7000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2152265025001387","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

Belantamab mafodotin is an anti-B cell maturation antigen (BCMA) immunoconjugate for patients with relapsed/refractory multiple myeloma (RRMM). Additional data on its treatment patterns, efficacy, and tolerability in real-world settings are needed.

Patients and Methods

This single-site, retrospective study examined 30 adults with multiple myeloma receiving care at Duke Cancer Institute who began belantamab mafodotin monotherapy between 8/5/2020 and 11/22/2022. We described baseline clinical characteristics, disease response (per International Myeloma Working Group [IMWG] criteria, as possible given available bone marrow biopsy data), belantamab mafodotin treatment patterns, and ocular adverse events (per the Keratopathy Visual Acuity [KVA] scale).

Results

Across 30 patients, the median number of lines of therapy was 4, 20 patients (87%) were triple-/quad-/penta-refractory, and 7 (23%) had high-risk cytogenetics (per IMWG criteria). Overall response rate was 67%. Progression occurred in 22 patients (73%); median progression-free survival was 9.5 months (95% CI 6.6-15.6). Median overall survival was not reached as of 3-year follow-up. Dose reduction occurred in 19 patients (63%); 65% were due to ocular adverse events, 30% hematologic adverse events. Cycle delay occurred in 28 (93%); 85% were due to ocular adverse events. Keratopathy (any grade) occurred in 28 (93%); 2% of events were grade ≥3. Visual acuity change (any grade) occurred in 27 (90%); 3.3% of events were grade ≥3. Treatment discontinuation from ocular toxicity occurred in 4 (13%).

Conclusion

Despite a high incidence of manageable keratopathy, these data demonstrate benefit in belantamab mafodotin in patients with RRMM over an extended time amid dose/cycle modifications.

Registration: ClinicalTrials.gov

NCT05986682.

查看原文本刊更多论文

贝兰他单抗马福多汀在复发和/或难治性多发性骨髓瘤患者中的治疗模式、疗效和耐受性：一项现实世界分析。

目的：Belantamab mafodotin是一种用于复发/难治性多发性骨髓瘤（RRMM）患者的抗b细胞成熟抗原（BCMA）免疫偶联物。需要更多关于其治疗模式、疗效和现实环境耐受性的数据。患者和方法：这项单点回顾性研究调查了30名在杜克癌症研究所接受治疗的多发性骨髓瘤患者，他们在2020年8月5日至2022年11月22日期间开始贝兰他单抗马弗多汀单药治疗。我们描述了基线临床特征、疾病反应（根据国际骨髓瘤工作组[IMWG]标准，尽可能提供骨髓活检数据）、贝兰他单抗治疗模式和眼部不良事件（根据角膜病变视力[KVA]量表）。结果：在30例患者中，治疗线的中位数为4条，20例患者（87%）为三难治性/四难治性/五难治性，7例患者（23%）为高危细胞遗传学（根据IMWG标准）。总有效率为67%。22例（73%）患者出现进展；中位无进展生存期为9.5个月（95% CI 6.6-15.6）。3年随访时，中位总生存期未达到。19例患者（63%）出现剂量减少；65%是眼部不良事件，30%是血液学不良事件。周期延迟28例（93%）；85%是由于眼部不良事件。角膜病变（任何级别）28例（93%）；2%的事件≥3级。视力（任何级别）改变27例（90%）；3.3%的事件为≥3级。4例（13%）因眼毒性而停止治疗。结论：尽管可控性角膜病变的发生率很高，但这些数据表明，在剂量/周期调整的较长时间内，贝兰他单马福多汀对RRMM患者有益。注册:临床试验。政府:NCT05986682。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.